Table 2.
Study Characteristics
| Study | RCT (Yes/No) |
Type of Glaucoma | Age, years (mean±SD) |
Sex (%) | Race (%) | Funding |
|---|---|---|---|---|---|---|
| 1. Okeke C et al.19 | Yes | OAG, ACG, OHTN, Glaucoma Suspect using Travatan | 1. Treatment Group: 66.2±13.1 2. Control Group: 63.8±13.4 |
1. Treatment Group: Male, 51.4% ; Female, 48.6% 2. Control Group: Male, 58.1%; Female, 41.9% |
1. Treatment Group: White, 34.3%; Black, 65.7% 2. Control Group: White 41.9%; Black, 54.8% |
NIH, Alcon, Wilmer Eye Institute, Bell Foundation Trust |
| 2. Sheppard J et al.21 | Yes | POAG, NTG, OHTN, PEX, Glaucoma Suspect with stable vision, fields and IOP for 1 year & ≤2 glaucoma meds | Total population: 73±11.3 | Not recorded | Not recorded | Not Recorded |
| 3. Norell SE.18 | Yes | Simple Chronic Glaucoma with elevated IOP, vision ≥20/60 & on pilocarpine tid | Total population: 73 | Total population: Male, 55%; Female 45% | Not recorded | Not Recorded |
| 4. Muir KW et al.17 | Yes | Any Type of Glaucoma with vision ≥20/200, without eye surgery in the last month and with a Mini-Mental Status Score ≥18 | 1. Treatment Group: 66±9.2 2. Control Group: 66±10.1 |
1. Treatment Group: Male, 100% 2. Control Group: Male, 99%; Female, 1% |
1. Treatment Group: White, 25%, Black 74%, Other, 1% 2. Control Group: White 33%, Black 64% |
NIH/NEI, Prevent Blindness America |
| 5. Cook PF et al.16 | No | Primary or Secondary Open-Angle Glaucoma on monotherapy with ≤80% adherence | Total population: 57.9±8.5 | Total population: Male, 50%; Female, 50% | Total population: White, 50%; Black, 50% | American Glaucoma Society, Pfizer |
| 6. Rendell J20 | No | POAG ≥40 years old | Total population: 68.5 | Total population: Male, 61%; Female, 39% | Total population: White, 70%; Black 30% | Not recorded |
| 7. Chen X et al.15 | No | Any Shanghai Glaucoma Club member or patient in Shanghai Glaucoma clinic | Glaucoma Club: 67 (median) Glaucoma Clinic: 57 (median) | Glaucoma Club: Male, 48%; Female, 52% Glaucoma Clinic: Male, 47%; Female, 53% | Not recorded | Not recorded |
| 8. Blondeau P et al.14 | No | Any patient in Dr. Blondeau’s glaucoma practice taking a glaucoma medication | Educational session: 67.1 Did not attend session: 69.2 | Not recorded | Not recorded | Allergan |
OAG=open-angle glaucoma, ACG= angle-closure glaucoma, OHTN=ocular hypertension, glc suspect = glaucoma suspect, POAG= primary open-angle glaucoma, NTG= normal-tension glaucoma, PEX=exfoliation syndrome glaucoma, IOP=intraocular pressure, NIH= National Institute of Health, NEI = National Eye Institute